- Home
- PHK vs SYRE Comparison
PHK vs SYRE Comparison
Compare PHK & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHK
- SYRE
- Stock Information
- Founded
- PHK 2003
- SYRE 2013
- Country
- PHK United States
- SYRE United States
- Employees
- PHK N/A
- SYRE N/A
- Industry
- PHK Finance/Investors Services
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- PHK Finance
- SYRE Health Care
- Exchange
- PHK Nasdaq
- SYRE Nasdaq
- Market Cap
- PHK 814.6M
- SYRE 841.4M
- IPO Year
- PHK N/A
- SYRE 2016
- Fundamental
- Price
- PHK $4.83
- SYRE $17.79
- Analyst Decision
- PHK
- SYRE Buy
- Analyst Count
- PHK 0
- SYRE 5
- Target Price
- PHK N/A
- SYRE $55.00
- AVG Volume (30 Days)
- PHK 491.5K
- SYRE 591.7K
- Earning Date
- PHK 01-01-0001
- SYRE 08-06-2025
- Dividend Yield
- PHK 12.61%
- SYRE N/A
- EPS Growth
- PHK N/A
- SYRE N/A
- EPS
- PHK N/A
- SYRE N/A
- Revenue
- PHK N/A
- SYRE N/A
- Revenue This Year
- PHK N/A
- SYRE N/A
- Revenue Next Year
- PHK N/A
- SYRE N/A
- P/E Ratio
- PHK N/A
- SYRE N/A
- Revenue Growth
- PHK N/A
- SYRE N/A
- 52 Week Low
- PHK $4.13
- SYRE $10.91
- 52 Week High
- PHK $5.15
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- PHK 58.93
- SYRE 61.20
- Support Level
- PHK $4.81
- SYRE $16.16
- Resistance Level
- PHK $4.85
- SYRE $18.31
- Average True Range (ATR)
- PHK 0.03
- SYRE 0.96
- MACD
- PHK 0.00
- SYRE 0.20
- Stochastic Oscillator
- PHK 77.78
- SYRE 84.18
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.